Hepatitis C virus (HCV) infection can be cured with pan-genotypic direct-acting antiviral agents. However, identifying individuals with current hepatitis C remains a major challenge, especially in resource-limited settings where access to or availability of molecular tests is still limited. The goal of this study was to develop and validate a molecular assay for the rapid detection of HCV RNA in resource-limited settings. It is based on a combination of reverse transcription loop-mediated isothermal amplification (RT-LAMP) with the clustered regularly interspaced short palindromic repeats–CRISPR-associated protein 12a (CRISPR–Cas12a) cleavage assay that allows the recognition of specific HCV nucleic acid sequences. Amplified products after the cleavage reactions can be visualized on lateral flow strips or measured with a fluorescence detector. When tested on clinical samples from individuals infected with HCV, HIV, or HBV, or from healthy donors, the RT-LAMP-coupled CRISPR–Cas12 assay yielded 96% sensitivity, 100% specificity, and 97% agreement as compared to the reference method (Roche COBAS AmpliPrep/COBAS TaqMan HCV Test). This assay could detect HCV RNA concentrations as low as 10 ng/µL (an estimated 2.38 Log10 IU/mL). Therefore, this sensitive and specific assay may represent an affordable and reliable point-of-care test for the identification of individuals with active hepatitis C in low-resource settings.
Since SARS-CoV-2 is a highly transmissible virus, a rapid and accurate diagnostic method is necessary to prevent virus spread. We aimed to develop and evaluate a new rapid colorimetric reverse transcription loop--mediated isothermal amplification (RT-LAMP) assay for SARS-CoV-2 detection in a single closed tube. Nasopharyngeal and throat swabs collected from at-risk individuals testing for SARS-CoV-2 were used to assess the sensitivity and specificity of a new RT-LAMP assay against a commercial qRT-PCR assay. Total RNA extracts were submitted to the RT-LAMP reaction under optimal conditions and amplified at 65 °C for 30 min using three sets of specific primers targeting the nucleocapsid gene. The reaction was detected using two different indicator dyes, hydroxynaphthol blue (HNB) and cresol red. A total of 82 samples were used for detection with HNB and 94 samples with cresol red, and results were compared with the qRT-PCR assay. The sensitivity of the RT-LAMP-based HNB assay was 92.1% and the specificity was 93.2%. The sensitivity of the RT-LAMP-based cresol red assay was 80.3%, and the specificity was 97%. This colorimetric feature makes this assay highly accessible, low-cost, and user-friendly, which can be deployed for massive scale-up and rapid diagnosis of SARS-CoV-2 infection, particularly in low-resource settings.
Since SARS-CoV-2 is a highly transmissible virus, a rapid and accurate diagnostic method is necessary to prevent virus spread. We aimed to develop and evaluate a new rapid colorimetric reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for SARS-CoV-2 detection in a single closed-tube. Nasopharyngeal and throat swabs collected from at-risk individuals testing for SARS-CoV-2 were used to assess the sensitivity and specificity of a new RT-LAMP assay against a commercial qRT-PCR assay. Total RNA extracts were submitted to the RT-LAMP reaction under optimal conditions and amplified at 65°C for 30 minutes using three sets of specific primers targeting the nucleocapsid gene. The reaction was detected using two different indicator dyes, hydroxynaphthol blue (HNB) and cresol red. A total of 82 samples were used for detection with HNB and 94 samples with cresol red, and results were compared with the qRT-PCR assay. The sensitivity of the RT-LAMP-based HNB assay was 92.1% and the specificity was 93.2%. The sensitivity of the RT-LAMP-based cresol red assay was 80.3%, and the specificity was 97%. This colorimetric feature makes this assay highly accessible, low-cost, and user-friendly, which can be deployed for massive scale-up and rapid diagnosis of SARS-CoV-2 infection, particularly in low-resource settings.
Severe acute respiratory infections (SARI) remain a major global health concern, particularly in resource-limited settings where comprehensive pathogen detection is challenging. Conventional diagnostics, including culture and multiplex PCR, are restricted to predefined targets and may miss emerging or uncommon pathogens. This study aimed to develop and optimize a practical long-read metagenomic next-generation sequencing (mNGS) workflow using Oxford Nanopore Technology for sputum samples from adults hospitalized with SARI. We evaluated sputum liquefaction, host nucleic acid depletion strategies, and SMART-9N-based cDNA amplification to enhance microbial and viral nucleic acid recovery. We found that dithiothreitol (DTT) treatment significantly improved nucleic acid extraction. DNase I treatment effectively reduced host background while preserving both viral and bacterial sequences, outperforming filtration-based approaches that reduced viral recovery. The optimized workflow enabled unbiased detection and strain-level resolution of respiratory pathogens, including rhinovirus C1/C42, human coronavirus HKU1, Mycoplasma pneumoniae, Haemophilus parainfluenzae, and Pseudomonas aeruginosa, with high genome coverage. This approach demonstrated robust performance for respiratory pathogen identification directly from sputum samples. The proposed workflow is scalable and suitable for clinical diagnostics and public health surveillance. Further validation in larger cohorts is warranted to assess diagnostic sensitivity, accuracy, and feasibility for routine implementation.
Background/Objectives: Access to hepatitis B virus (HBV) DNA testing remains limited in resource-limited settings. The main reasons for this are the high cost of molecular assays and the need for specialized infrastructure. This pilot study aimed to preliminarily develop and evaluate simple HBV DNA extraction methods combined with the colorimetric loop-mediated isothermal amplification (LAMP) technique. Methods: Three extraction methods were evaluated: (i) boiling-based, (ii) paper-based, and (iii) an adapted magnetic bead-based extraction method. Preliminary analytical performance was assessed using serially diluted HBV DNA-positive pooled plasma. Detection performance was evaluated using 40 clinical plasma specimens, including 35 HBV DNA-positive and 5 HBV DNA-negative samples, with real-time PCR as the reference standard. Results: The preliminary analytical detection level observed under the tested conditions was 105 IU/mL for the LAMP methods using boiling- or paper-based extraction, while it was 103 IU/mL with the adapted magnetic bead-based extraction–LAMP method. Evaluation using clinical specimens showed sensitivities of 43%, 54%, and 63%, respectively. Detection was dependent on viral load, with the highest detection observed among specimens with HBV DNA concentrations above 105 IU/mL. Conclusions: In this laboratory pilot, the workflows showed viral-load-dependent qualitative detection, with the adapted magnetic bead-based workflow yielding the highest observed detection rate. These findings require confirmation through formal analytical validation and larger, independent clinical studies before any clinical or implementation use can be considered.
Background: Hepatitis C virus (HCV) remains a significant public health concern in Thailand, with genotype-specific, drug-dependent variations influencing treatment response and disease progression. Despite the availability of pan-genotypic direct-acting antivirals (DAAs), genotype surveillance remains essential for optimizing national elimination strategies. This study thus aims to characterize the molecular distribution of HCV genotypes in northern Thailand. Methods: We conducted a retrospective molecular epidemiological study on 1737 HCV-infected patients who attended the Clinical Microbiology Service Unit (CMSU) Laboratory, Faculty of Associated Medical Sciences, Chiang Mai University between April 2016 and June 2024. HCV genotyping was performed using Sanger sequencing and reverse hybridization line probe assay (LiPA). Results: Genotype 3 was the most prevalent (36.6%), followed by genotype 1 (35.8%) and genotype 6 (27.2%). Subtype 3a (27.2%) predominated, along with 1a (22.1%), 1b (12.6%), and genotype 6 subtypes including 6c to 6l (13.5%) and 6n (6.6%). Males had a higher prevalence of genotype 1, while genotype 3 was more common among females. Temporal analysis revealed a relative increase in genotype 6 prevalence since 2021. Genotype 6 also exhibited significantly higher median viral loads compared to genotypes 1 and 3 (p < 0.0001). Conclusions: This study provides updated evidence on the shifting distribution of HCV genotypes in northern Thailand, particularly the increasing prevalence of genotype 6. These findings underscore the importance of continued molecular surveillance to guide genotype-specific treatment strategies and support Thailand’s 2030 HCV elimination goals.